Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics
Adds LNG-451, a highly selective brain-penetrant precision therapy targeting EGFR exon 20 insertion mutations, to Blueprint Medicines' lung cancer pipeline
Lengo Therapeutics on track to submit IND to FDA for LNG-451 by the end of 2021
Lengo Therapeu... Biopharmaceuticals, Oncology, Mergers & Acquisitions Blueprint Medicines, Lengo Therapeutics, precision therapy, NSCLC
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Lung Cancer | Mergers and Aquisitions | Neurology | Non-Small Cell Lung Cancer | Pharmaceuticals